FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When ...

Dr Hilary Jones has said that the prevalence of gout is set to increase up to 70 per cent in the coming years - and ...

The current strategy for managing chronic gout is the use of uric-acid-lowering drugs to reduce urate production or of a uricosuric agent to promote renal uric acid excretion. Probenecid is ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...

The NHS has listed what it believes to be the 20 top most painful conditions a person can suffer from. While there are ...

Urate-lowering therapies benefited patients with gout and stage 3 chronic kidney disease without raising the risk of kidney ...

Uric acid crystals can accumulate under the skin and form lumps called "tophi." Chronic (long-term) gout can cause knee ...

The refractory gout market is growing because of the rising prevalence of gout brought on by aging populations and changes in ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

The global intravenous pegloticase market is poised for substantial growth, projected to reach USD 11.61 Billion by 2033 from ...